MSCT for refractory SLE

Umbilical cord mesenchymal stem cell transplantation in active and refractory systemic lupus erythematosus: a multicenter clinical study
Dandan Wang, et al. (Beike Biotechnology Co., Ltd.)
Arthritis Research & Therapy 2014, 16:R79
http://arthritis-research.com/content/16/2/R79

Conclusion: UC-MSCT results in satisfactory clinical response in SLE patients.
However, in our present study, several patients experienced disease relapse after 6 months, indicating the necessity to repeat MSCT after 6 months.

MSCs are multipotent, nonhematopoietic progenitor cells that are currently being explored as a promising new treatment for tissue regeneration. Although their immunomodulatory properties are not yet completely understood, their low immunogenic potential, together with their effects on immune responses, make them a promising therapeutic tool for the treatment of patients with severe and refractory autoimmune diseases.

related:
Stem-Cell Therapy in China Draws Foreign Patients
March 18, 2008
http://www.npr.org/templates/story/story.php?storyId=88123868

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s